FIELD: biotechnology; genetic engineering; immunology.
SUBSTANCE: tetravalent vector vaccine has been obtained for the prevention of dengue fever, containing a recombinant vector based on a modified vaccinia virus strain Ankara (MVA) with an integrated nucleotide sequence encoding the d34 antigen (46.5 kDa), which consists of four DHI domains of the E-protein of dengue virus serotypes 1, 2, 3 and 4, connected by a flexible linker 2x(GGGGS).
EFFECT: method has been proposed for using a tetravalent vector vaccine to induce a specific immune response against four serotypes of the dengue virus, including administering the vaccine into the body of a mammal in an effective dosage.
2 cl, 5 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SET OF CONSERVATIVE EPITOPES OF VIRAL PROTEINS, METHOD OF THEIR IDENTIFICATION AND SELECTION, VACCINE COMPOSITION AND METHOD OF VACCINATION | 2022 |
|
RU2814020C2 |
| RECOMBITANT PLASMID DNA pET21-VP40VE CONTAINING THE GENE FOR THE MATRIX PROTEIN VP40 OF EBOLA VIRUS AND THE RECOMBITANT PROTEIN VP40-VE OBTAINED AS A RESULT OF THE GENE EXPRESSION FOR THE PROTEIN VP40 OF EBOLA VIRUS USING THE RECOMBITANT PLASMID DNA pET21-VP40VE AND EXHIBITING IMMUNOGENIC AND ANTIGENIC PROPERTIES | 2020 |
|
RU2742511C1 |
| RECOMBINANT PLASMID VECTOR pET32-WNV-DIII, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT DOMAIN III OF STRUCTURAL GLYCOPROTEIN E OF WEST NILE VIRUS IN ESCHERICHIA COLI CELLS, ESCHERICHIA COLI BL21(DE3)-DIII-WNV CELL LINE STRAIN AND DIII-WNV RECOMBINANT PROTEIN FOR PREPARING IMMUNOBIOLOGICAL PREPARATIONS | 2024 |
|
RU2821341C1 |
| EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS 5 SEROTYPE, INDUCING CROSS-PROTECTIVE IMMUNITY TO INFLUENZA A VIRUSES OF SUBTYPE H1, AND A PHARMACEUTICAL COMPOSITION BASED ON IT | 2023 |
|
RU2802753C1 |
| IMMUNOBIOLOGICAL AGENT FOR THE PREVENTION OF DISEASES CAUSED BY TICK-BORNE ENCEPHALITIS VIRUS BASED ON A RECOMBINANT VIRUS OF THE GENUS FLAVIVIRUS | 2022 |
|
RU2795800C1 |
| EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS SEROTYPE 5 INDUCING CROSS-PROTECTIVE IMMUNITY TO INFLUENZA A SUBTYPE H3 VIRUSES AND PHARMACEUTICAL COMPOSITION BASED ON IT | 2023 |
|
RU2814189C1 |
| METHOD OF PREPARING IMMUNOGENIC COMPOSITION BASED ON THREE FUSION PROTEINS OF SHELL OF TICK-BORNE ENCEPHALITIS VIRUS DEFINING BELONGING TO SIBERIAN (DBD2-D3S), EUROPEAN (DBD2-D3E) AND FAR EAST (DBD2-D3D) VIRUS SUBTYPES; RECOMBINANT PLASMIDS pDBD2-D3S, pDBD2-D3E AND pDBD2-D3D; PRODUCER STRAINS Escherichia coli M15 [pREP4]; CHIMERIC PROTEINS AND THEIR APPLICATION | 2014 |
|
RU2560588C1 |
| METHOD FOR PRESENTATION OF VIRAL ANTIGEN IN IMMUNE SYSTEM OF HOST BASED ON PROTEASOME-MEDIATED TECHNOLOGY DESIGNATED FOR DEVELOPMENT OF METHODS OF BIOLOGICAL PROTECTION | 2004 |
|
RU2275937C1 |
| RECOMBINANT PLASMID DNA PET21-NPVE CONTAINING NUCLEOLOPROTEIN (NP) GENE OF EBOLA VIRUS AND RECOMBINANT PROTEIN NP-VE, OBTAINED AS RESULT OF EXPRESSION OF NP GENE OF EBOLA VIRUS USING RECOMBINANT PLASMID DNA PET21-NPVE AND POSSESSING IMMUNOGENIC AND ANTIGENIC PROPERTIES | 2020 |
|
RU2739505C1 |
| METHOD OF PRODUCING ANTIGEN OF ZIKA VIRUS, HAVING IMMUNOGENIC AND ANTIGENIC PROPERTIES | 2019 |
|
RU2717993C1 |
